Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Therapeutic strategies for and clinical outcomes in iliopsoas muscle abscess: A systematic review and meta-analysis.

Created on 11 Aug 2026

Authors

Wan-Ling Cheng, Chuan-Ju Lin, Shu-Ting Huang, Kuei Chen

Published in

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. Aug 06, 2026. Epub Aug 06, 2026.

Abstract

This systematic review and meta-analysis evaluated therapeutic strategies for iliopsoas muscle abscess (IPA). Overall treatment success and mortality rates were 80.4% and 8.3%, respectively, with mortality escalating in complex cases. Modality-specific descriptive estimates showed mortality rates of 4.2% for percutaneous catheter drainage (PCD), 6.2% for open surgical drainage (OSD), and 12.7% for antibiotic monotherapy, with corresponding treatment success rates of 71.4%, 92.0%, and 64.6%, respectively. Length of hospital stay and recurrence were summarized descriptively because of inconsistent definitions and reporting across studies. Staphylococcus species were the most frequently identified pathogens among evaluable pus cultures (38.1%), with S. aureus predominating in primary IPA. In contrast, IPA of gastrointestinal or genitourinary origin was more frequently associated with Enterobacteriaceae. These findings support prompt risk stratification and individualized management based on abscess etiology, morphology, and local microbiology.

PMID:
42575815
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement